{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:07:58Z","timestamp":1792843678721,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,3,20]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> In this first-in-human phase I study, patients with advanced solid tumors or lymphomas received milademetan orally once daily as extended\/continuous (days 1-21 or 1-28 every 28 days) or intermittent (days 1-7, or days 1-3 and 15-17 every 28 days) schedules. The primary objective was to determine the recommended phase II dose and schedule. Secondary objectives included tumor response according to standard evaluation criteria. Predefined analyses by tumor type were performed. Safety and efficacy analyses included all patients who received milademetan. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Between July 2013 and August 2018, 107 patients were enrolled and received milademetan. The most common grade 3\/4 drug-related adverse events were thrombocytopenia (29.0%), neutropenia (15.0%), and anemia (13.1%). Respective rates at the recommended dose and schedule (260 mg once daily on days 1-3 and 15-17 every 28 days, ie, 3\/14 days) were 15.0%, 5.0%, and 0%. Across all cohorts (N = 107), the disease control rate was 45.8% (95% CI, 36.1 to 55.7) and median progression-free survival was 4.0 months (95% CI, 3.4 to 5.7). In the subgroup with dedifferentiated liposarcomas, the disease control rate and median progression-free survival were 58.5% (95% CI, 44.1 to 71.9) and 7.2 months overall (n = 53), and 62.0% (95% CI, 35.4 to 84.8) and 7.4 months with the recommended intermittent schedule (n = 16), respectively. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> An intermittent dosing schedule of 3\/14 days of milademetan mitigates dose-limiting hematologic abnormalities while maintaining efficacy. Notable single-agent activity with milademetan in dedifferentiated liposarcomas has prompted a randomized phase III trial (MANTRA). <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.22.01285","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T21:00:27Z","timestamp":1674248427000},"page":"1714-1724","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":103,"title":["A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct01877382","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8468-0119","authenticated-orcid":false,"given":"Mrinal M.","family":"Gounder","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3078-5043","authenticated-orcid":false,"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Columbia University Vagelos School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Weise","sequence":"additional","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute, Karmanos Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Smillow Cancer Hospital at Yale-New Haven, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna","family":"Kumar","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tao","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hong","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Patel","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasong","family":"Lu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Lesegretain","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc, Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-8858","authenticated-orcid":false,"given":"Vijaya G.","family":"Tirunagaru","sequence":"additional","affiliation":[{"name":"Rain Oncology Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[{"name":"Rain Oncology Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Doebele","sequence":"additional","affiliation":[{"name":"Rain Oncology Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1038\/358015a0"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.7555\/JBR.27.20130030"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.07.005"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026104"},{"key":"b5","author":"Kato S","journal-title":"JCO Precis Oncol"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.15.3453"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.014"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091283"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00874-y"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0949"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3230"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.2307\/2531628"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.2307\/2532905"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1177\/1740774508096474"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70474-6"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.005"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00840-1"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7117"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00869-2"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01444-4"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2013.11.012"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1295"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01141-2"},{"key":"b25","first-page":"1023","volume":"2","author":"Yang H","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14875"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2098"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.010"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13669"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.07.023"},{"key":"b31","volume-title":"NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma (ed Version 2.2021)","author":"National Comprehensive Cancer Network","year":"2021"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6605"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0264"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5476"},{"key":"b36","volume":"15","author":"Dickson MA","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.01285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T22:01:46Z","timestamp":1678917706000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.01285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,3,20]]}},"alternative-id":["10.1200\/JCO.22.01285"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.01285","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"2022-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}